Please login to the form below

Not currently logged in
Email:
Password:

Akynzeo

This page shows the latest Akynzeo news and features for those working in and with pharma, biotech and healthcare.

Merck plans expanded filing for Emend this year

Merck plans expanded filing for Emend this year

Generics aside, competition is building in the CINV sector. Last October the FDA approved Eisai's combination Akynzeo (netupitant and palonosterol), while Tesaro's oral and injectable NK1 antagonist rolapitant was

Latest news

  • Eisai wins US approval for chemotherapy side effects drug Eisai wins US approval for chemotherapy side effects drug

    Eisai wins US approval for chemotherapy side effects drug. FDA backs Akynzeo to treat nausea and vomiting. ... Combined, these studies involved 1, 720 people receiving chemotherapy, with groups split between those taking Akynzeo and those on Aloxi.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics